Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Burak
Kelly W
KW
Liver Unit, Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Canada. kwburak@ucalgary.ca
Thomas
Melanie B
MB
Zhu
Andrew X
AX
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003245:Consensus Statements as Topic; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000628:therapy*; D016031:Liver Transplantation; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D018579:Patient Selection; D010671:Phenylurea Compounds; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011878:Radiotherapy; D000077157:Sorafenib; D016896:Treatment Outcome; D015019:Yttrium / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D019275:Radiopharmaceuticals; D009536:Niacinamide; D015019:Yttrium; D000077157:Sorafenib